Extavia Market Report 2026

Extavia Market Overview

• The Extavia market growth in the historic period has been driven by early approval of interferon beta therapies, rising ms prevalence • Market expansion is supported by increasing ms diagnosis rates, growth in combination therapy approaches • Growth Driver: Rising Multiple Sclerosis Prevalence Fuels Growth Of The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Extavia Market?

Extavia refers to a brand name for interferon beta-1b, a medication used primarily for the treatment of multiple sclerosis (MS). It is designed to reduce the frequency of relapses and slow the progression of physical disability in individuals with relapsing forms of MS, including relapsing-remitting MS and secondary-progressive MS with active relapses. The main clinical indications of extavia are relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), and other multiple sclerosis forms. Relapsing-remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis (MS), a chronic neurological condition affecting the central nervous system (CNS). It is distributed through hospital pharmacies, specialty pharmacies, and online pharmacies and is applicable for subcutaneous injection, long-term disease management, and prophylactic use.

What Is The Extavia Market Growth Forecast?

The growth in the forecast period can be attributed to increasing ms diagnosis rates, growth in combination therapy approaches, expansion of specialty neurology care, improved patient adherence programs, continued demand in established markets. Major trends in the forecast period include continued use of interferon therapies, emphasis on long term ms management, focus on relapse reduction strategies, sustained demand for injectable treatments, expansion of disease modifying therapies.

Global Extavia Market Segmentation

1) By Clinical Indication: Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Other Multiple Sclerosis Forms 2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies 3) By Application: Subcutaneous Injection, Long-Term Disease Management, Prophylactic Use

What Are The Drivers Of The Extavia Market?

The increasing prevalence of multiple sclerosis is expected to propel the growth of the extavia market going forward. Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), which includes the brain and spinal cord. The increasing prevalence of multiple sclerosis (MS) can be attributed to a combination of factors, including better diagnostic tools, greater awareness, and potential changes in environmental and lifestyle factors. Extavia is a medication containing interferon beta-1b, used to treat relapsing-remitting multiple sclerosis (RRMS) by reducing the frequency of relapses and slowing disease progression through subcutaneous injections. For instance, in January 2023, according to the SingleCare Administrators, a US-based licensed discount medical plan organization, in the United States, nearly 1 million individuals were impacted by MS, with over 2.8 million people estimated to be living with the condition globally. Therefore, the increasing prevalence of multiple sclerosis is driving the growth of the extavia industry. The growing adoption of personalized medicine is anticipated to drive the future growth of the extavia market in future years. Personalized medicines refer to treatments tailored to an individual's genetic makeup, lifestyle, and specific health conditions, aiming for more effective and precise care. The rising adoption of personalized medicine is driven by its ability to offer more effective, targeted treatments with fewer side effects. Personalized medicine drives extavia by enabling tailored treatment plans that optimize efficacy and improve outcomes for multiple sclerosis patients. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, in 2023, the FDA approved 16 new personalized treatments for rare diseases, up from six in 2022. Therefore, the rising adoption of personalized medicines is driving the growth of the extavia industry. Rising investments in healthcare are expected to boost the growth of the extavia market going forward. Healthcare investments refer to the allocation of financial resources toward entities, technologies, services, or innovations in the healthcare sector. Healthcare investments are rising due to increasing demand for chronic disease management from aging populations and funding for advanced technologies such as telemedicine to improve healthcare delivery. Higher healthcare spending supports the use of Extavia by enabling broader access to disease-modifying therapies for multiple sclerosis, allowing healthcare systems to invest in long-term treatment, monitoring, and supportive care needed to manage chronic neurologic conditions. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, marking a significant rise compared to the 0.9% growth seen in 2022. Therefore, rising investments in healthcare are driving the growth of the extavia industry.

Key Players In The Global Extavia Market

Major companies operating in the extavia market are Novartis AG

Regional Insights

North America was the largest region in the extavia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Extavia Market?

The extavia market consists of sales of extavia solutions for injection, extavia injection kits, auto-injector devices, and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Extavia Market Report 2026?

The extavia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the extavia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.